---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093933"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:55:18.559100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025

## Summary
- Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.
- Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.
- Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.
- R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.
- Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-093933
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/0000950170-24-093933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/xene-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093933
- JSON: https://secwatch.observer/filing/0000950170-24-093933.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.